US Stocks: Rocket Pharma shares fall 15% despite FDA nod for childhood disorder treatment

The pharma sector is currently seeing interest in 'Best Pharma Stocks' and 'Multibaggers' (as per online context), indicating a positive sentiment. However, this US news highlights that regulatory approval alone isn't sufficient for sustained stock performance; commercial viability and market access are crucial.

• •Rocket Pharmaceuticals' shares fell 15% despite FDA approval for Kresladi, a gene therapy.
• •The drug is for a rare childhood immune disorder (Leukocyte Adhesion Deficiency-I).
• •Investors are concerned about practical challenges limiting patient access.
• •The company plans a phased launch with limited availability.
• •Risk flag: Challenges in commercialization and patient access for novel therapies.